Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

SCT in Jehovah's Witnesses: the bloodless transplant

Bone Marrow Transplantation volume 41, pages 837–844 (2008)Cite this article

Abstract

Auto-SCT and Allo-SCT are procedures conventionally associated with intensive transfusion support. This dependence has historically prevented SCT in individuals with religious or personal objections to transfusion. More recently, a growing body of literature supports the feasibility of ‘bloodless transplants’: SCT without the transfusion of RBCs, plts or plasma. It is possible to perform ‘bloodless’ autologous or reduced-intensity allogeneic transplants in properly selected patients. The success of these procedures depends on the transplantation technique and on meticulous attention to blood conservation and supportive care. In this study, the literature supporting bloodless transplantation will be reviewed. Supportive measures such as the optimal stimulation of erythropoiesis and thrombopoiesis in the transplant patient will be discussed, as will the prevention and management of bleeding during extreme thrombocytopenia. Many of these techniques, learned and refined in Jehovah's Witnesses, may help reduce bleeding and transfusion requirements in the general transplant population.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Helm RE, Rosengart TK, Gomez M, Klemperer JD, DeBois WJ, Velasco F et al. Comprehensive multimodality blood conservation: 100 consecutive CABG operations without transfusion. Ann Thorac Surg 1998; 65: 125–136.

    Article  CAS  PubMed  Google Scholar 

  2. Jabbour N, Gagandeep S, Shah H, Mateo R, Stapfer M, Genyk Y et al. Impact of a transfusion-free program on non-Jehovah's Witness patients undergoing liver transplantation. Arch Surg 2006; 141: 913–917.

    Article  PubMed  Google Scholar 

  3. Report of Jehovah's Witnesses Worldwide. The Watchtower, 2006.

  4. Genesis 9:3–5. Holy Bible. King James Version.

  5. Muramoto O . Bioethical aspects of the recent changes in the policy of refusal of blood by Jehovah's witnesses. BMJ 2001; 322: 37–39.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Findley LJ, Redstone PM . Blood transfusion in adult Jehovah's Witnesses. A case study of one congregation. Arch Intern Med 1982; 142: 606–607.

    Article  CAS  PubMed  Google Scholar 

  7. Elder L . Why some Jehovah's Witnesses accept blood and conscientiously reject official Watchtower Society blood policy. J Med Ethics 2000; 26: 375–380.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Gyamfi C, Berkowitz RL . Responses by pregnant Jehovah's Witnesses on health care proxies. Obstet Gynecol 2004; 104: 541–544.

    Article  PubMed  Google Scholar 

  9. Stowell C, Sazama K . Informed Consent in Blood Transfusion and Cellular Therapies. AABB: Bethesda, MD, 2007, p 103.

    Google Scholar 

  10. Anderson NL, Polanski M, Pieper R, Gatlin T, Tirumalai RS, Conrads TP et al. The human plasma proteome: a nonredundant list developed by combination of four separate sources. Mol Cell Proteomics 2004; 3: 311–326.

    Article  CAS  PubMed  Google Scholar 

  11. Watch Tower Bible and Tract Society. Watchtower 2000; Jun 15: 29–31.

    Google Scholar 

  12. Patriarca F, Damiani D, Fanin R, Grimaz S, Geromin A, Cerno M et al. High-dose therapy in multiple myeloma: effect of positive selection of CD34+ peripheral blood stem cells on hematologic engraftment and clinical outcome. Haematologica 2000; 85: 269–274.

    CAS  PubMed  Google Scholar 

  13. Marsh JC, Bevan DH . Haematological care of the Jehovah's Witness patient. Br J Haematol 2002; 119: 25–37.

    Article  PubMed  Google Scholar 

  14. Knuti KA, Amrein PC, Chabner BA, Lynch Jr TJ, Penson RT . Faith, identity, and leukemia: when blood products are not an option. Oncologist 2002; 7: 371–380.

    Article  PubMed  Google Scholar 

  15. Estrin JT, Ford PA, Henry DH, Stradden AP, Mason BA . Erythropoietin permits high-dose chemotherapy with peripheral blood stem-cell transplant for a Jehovah's Witness. Am J Hematol 1997; 55: 51–52.

    Article  CAS  PubMed  Google Scholar 

  16. Kerridge I, Lowe M, Seldon M, Enno A, Deveridge S . Clinical and ethical issues in the treatment of a Jehovah's Witness with acute myeloblastic leukemia. Arch Intern Med 1997; 157: 1753–1757.

    Article  CAS  PubMed  Google Scholar 

  17. Mazza P, Prudenzano A, Amurri B, Palazzo G, Pisapia G, Stani L et al. Myeloablative therapy and bone marrow transplantation in Jehovah's Witnesses with malignancies: single center experience. Bone Marrow Transplant 2003; 32: 433–436.

    Article  CAS  PubMed  Google Scholar 

  18. Sefcick A, Byrne JL, Russell NH . High-dose chemotherapy and autologous peripheral blood stem cell transplantation in lymphoma without blood product support. Bone Marrow Transplant 2000; 26: 1140–1141.

    Article  CAS  PubMed  Google Scholar 

  19. Ballen KK, Becker PS, Yeap BY, Matthews B, Henry DH, Ford PA . Autologous stem-cell transplantation can be performed safely without the use of blood-product support. J Clin Oncol 2004; 22: 4087–4094.

    Article  PubMed  Google Scholar 

  20. Brown NM, Matthews B, Ford PA . Treatment of a Jehovah's Witness using a transfusion-free autologous stem cell transplant protocol. Community Oncol 2006; 3: 776–781.

    Article  Google Scholar 

  21. Wandt H, Schaefer-Eckart K, Wilhelm M . Two allogeneic hematopoietic stem cell transplantations without the use of blood-product support. Haematologica 2005; 90: 1292–1294.

    PubMed  Google Scholar 

  22. Ciurea S, Beri R, Dobogai L, Chunduri S, Mahmud N, Rondelli D et al. The use of blood conservation methods in addition to erythropoietin allows myeloablative allogeneic stem cell transplantation without the use of blood products. Bone Marrow Transplant 2006; 37: 325–327.

    Article  CAS  PubMed  Google Scholar 

  23. Zenz T, Dohner H, Bunjes D . Transfusion-free reduced-intensity conditioned allogeneic stem cell transplantation in a Jehovah's witness. Bone Marrow Transplant 2003; 32: 437–438.

    Article  CAS  PubMed  Google Scholar 

  24. Smith SE, Toor A, Rodriguez T, Stiff P . The administration of polymerized human hemoglobin (pyridoxylated) to a Jehovah's Witness after submyeloablative stem cell transplantation complicated by delayed graft failure. Compr Ther 2006; 32: 172–175.

    Article  PubMed  Google Scholar 

  25. Weissinger F, Sandmaier BM, Maloney DG, Bensinger WI, Gooley T, Storb R . Decreased transfusion requirements for patients receiving nonmyeloablative compared with conventional peripheral blood stem cell transplants from HLA-identical siblings. Blood 2001; 98: 3584–3588.

    Article  CAS  PubMed  Google Scholar 

  26. Stanworth SJ, Hyde C, Heddle N, Rebulla P, Brunskill S, Murphy MF . Prophylactic platelet transfusion for haemorrhage after chemotherapy and stem cell transplantation. Cochrane Database Syst Rev 2004, Issue 4, Art No. CD004269.

  27. Wandt H, Schaefer-Eckart K, Frank M, Birkmann J, Wilhelm M . A therapeutic platelet transfusion strategy is safe and feasible in patients after autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 2006; 37: 387–392.

    Article  CAS  PubMed  Google Scholar 

  28. Langenmayer I, Weaver C, Buckner CD, Lilleby K, Appelbaum FR, Longin K et al. Engraftment of patients with lymphoid malignancies transplanted with autologous bone marrow, peripheral blood stem cells or both. Bone Marrow Transplant 1995; 15: 241–246.

    CAS  PubMed  Google Scholar 

  29. Weaver CH, Hazelton B, Birch R, Palmer P, Allen C, Schwartzberg L et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 1995; 86: 3961–3969.

    CAS  PubMed  Google Scholar 

  30. Meldgaard Knudsen L, Jensen L, Jarlbaek L, Hansen PG, Hansen SW, Drivsholm L et al. Subsets of CD34+ hematopoietic progenitors and platelet recovery after high dose chemotherapy and peripheral blood stem cell transplantation. Haematologica 1999; 84: 517–524.

    CAS  PubMed  Google Scholar 

  31. Sartor MM, Garvin F, Antonenas V, Bradstock KF, Gottlieb DJ . Failure to achieve a threshold dose of CD34(+)CD110(+) progenitor cells in the graft predicts delayed platelet engraftment after autologous stem cell transplantation. Bone Marrow Transplant 2007; 40: 851–857.

    Article  CAS  PubMed  Google Scholar 

  32. Cashen AF, Lazarus HM, Devine SM . Mobilizing stem cells from normal donors: is it possible to improve upon G-CSF? Bone Marrow Transplant 2007; 39: 577–588.

    Article  CAS  PubMed  Google Scholar 

  33. Bernstein SH, Nademanee AP, Vose JM, Tricot G, Fay JW, Negrin RS et al. A multicenter study of platelet recovery and utilization in patients after myeloablative therapy and hematopoietic stem cell transplantation. Blood 1998; 91: 3509–3517.

    CAS  PubMed  Google Scholar 

  34. Bolwell BJ, Goormastic M, Andresen S, Overmoyer B, Pohlman B, Kalaycio M . Platelet transfusion requirements during autologous peripheral blood progenitor cell transplantation correlate with the pretransplant platelet count. Bone Marrow Transplant 1997; 20: 459–463.

    Article  CAS  PubMed  Google Scholar 

  35. Bolwell B, Goormastic M, Andresen S, Koo A, Wise K, Overmoyer B et al. Variables associated with the platelet count 6 weeks after autologous peripheral blood progenitor cell transplantation. Bone Marrow Transplant 1998; 22: 547–551.

    Article  CAS  PubMed  Google Scholar 

  36. Ruiz-Arguelles GJ, Morales-Toquero A, Lopez-Martinez B, Tarin-Arzaga LD, Manzano C . Bloodless (transfusion-free) hematopoietic stem cell transplants: the Mexican experience. Bone Marrow Transplant 2005; 36: 715–720.

    Article  CAS  PubMed  Google Scholar 

  37. Spitzer G, Adkins DR, Spencer V, Dunphy FR, Petruska PJ, Velasquez WS et al. Randomized study of growth factors post-peripheral-blood stem-cell transplant: neutrophil recovery is improved with modest clinical benefit. J Clin Oncol 1994; 12: 661–670.

    Article  CAS  PubMed  Google Scholar 

  38. Khoury HJ, Loberiza Jr FR, Ringden O, Barrett AJ, Bolwell BJ, Cahn JY et al. Impact of posttransplantation G-CSF on outcomes of allogeneic hematopoietic stem cell transplantation. Blood 2006; 107: 1712–1716.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Du X, Williams DA . Interleukin-11: review of molecular, cell biology, and clinical use. Blood 1997; 89: 3897–3908.

    CAS  PubMed  Google Scholar 

  40. Vredenburgh JJ, Hussein A, Fisher D, Hoffman M, Elkordy M, Rubin P et al. A randomized trial of recombinant human interleukin-11 following autologous bone marrow transplantation with peripheral blood progenitor cell support in patients with breast cancer. Biol Blood Marrow Transplant 1998; 4: 134–141.

    Article  CAS  PubMed  Google Scholar 

  41. Schuster MW, Beveridge R, Frei-Lahr D, Abboud CN, Cruickshank S, Macri M et al. The effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) on platelet recovery in breast cancer patients undergoing autologous bone marrow transplantation. Exp Hematol 2002; 30: 1044–1050.

    Article  CAS  PubMed  Google Scholar 

  42. Bolwell B, Vredenburgh J, Overmoyer B, Gilbert C, Chap L, Menchaca DM et al. Phase 1 study of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in breast cancer patients after autologous peripheral blood progenitor cell (PBPC) transplantation. Bone Marrow Transplant 2000; 26: 141–145.

    Article  CAS  PubMed  Google Scholar 

  43. Nash RA, Kurzrock R, DiPersio J, Vose J, Linker C, Maharaj D et al. A phase I trial of recombinant human thrombopoietin in patients with delayed platelet recovery after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2000; 6: 25–34.

    Article  CAS  PubMed  Google Scholar 

  44. Kuter DJ . New thrombopoietic growth factors. Blood 2007; 109: 4607–4616.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Weiskopf RB, Kramer JH, Viele M, Neumann M, Feiner JR, Watson JJ et al. Acute severe isovolemic anemia impairs cognitive function and memory in humans. Anesthesiology 2000; 92: 1646–1652.

    Article  CAS  PubMed  Google Scholar 

  46. Weiskopf RB, Feiner J, Hopf HW, Viele MK, Watson JJ, Kramer JH et al. Oxygen reverses deficits of cognitive function and memory and increased heart rate induced by acute severe isovolemic anemia. Anesthesiology 2002; 96: 871–877.

    Article  PubMed  Google Scholar 

  47. Leung JM, Weiskopf RB, Feiner J, Hopf HW, Kelley S, Viele M et al. Electrocardiographic ST-segment changes during acute, severe isovolemic hemodilution in humans. Anesthesiology 2000; 93: 1004–1010.

    Article  CAS  PubMed  Google Scholar 

  48. Carson JL, Poses RM, Spence RK, Bonavita G . Severity of anaemia and operative mortality and morbidity. Lancet 1988; 1: 727–729.

    Article  CAS  PubMed  Google Scholar 

  49. Viele MK, Weiskopf RB . What can we learn about the need for transfusion from patients who refuse blood? The experience with Jehovah's Witnesses. Transfusion 1994; 34: 396–401.

    Article  CAS  PubMed  Google Scholar 

  50. Perez-de-Sa V, Roscher R, Cunha-Goncalves D, Larsson A, Werner O . Mild hypothermia has minimal effects on the tolerance to severe progressive normovolemic anemia in Swine. Anesthesiology 2002; 97: 1189–1197.

    Article  PubMed  Google Scholar 

  51. McLoughlin PL, Cope TM, Harrison JC . Hyperbaric oxygen therapy in the management of severe acute anaemia in a Jehovah's witness. Anaesthesia 1999; 54: 891–895.

    Article  CAS  PubMed  Google Scholar 

  52. Campbell R, Marik PE . Severe autoimmune hemolytic anemia treated by paralysis, induced hypothermia, and splenic embolization. Chest 2005; 127: 678–681.

    Article  PubMed  Google Scholar 

  53. Baron F, Frere P, Fillet G, Beguin Y . Tandem high-dose therapy (HDT) for multiple myeloma: recombinant human erythropoietin therapy given between first and second HDT allows second peripheral blood stem cell transplantation without red blood cell transfusion. Br J Haematol 2003; 123: 103–105.

    Article  CAS  PubMed  Google Scholar 

  54. Xenocostas A, Yee A, Wong CJ, Sutton DM, Lipton JH, Kiss TL et al. RBC transfusion requirements after allogeneic marrow transplantation: impact of the before-transplant Hb level on transfusion and early survival. Transfusion 2003; 43: 373–382.

    Article  PubMed  Google Scholar 

  55. Ivanov V, Faucher C, Mohty M, Bilger K, Ladaique P, Sainty D et al. Decreased RBCTs after reduced intensity conditioning allogeneic stem cell transplantation: predictive value of prior Hb level. Transfusion 2004; 44: 501–508.

    Article  CAS  PubMed  Google Scholar 

  56. Bucaneve G, Micozzi A, Menichetti F, Martino P, Dionisi MS, Martinelli G et al. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med 2005; 353: 977–987.

    Article  CAS  PubMed  Google Scholar 

  57. Evens AM, Bennett CL, Luminari S . Epoetin-induced pure red-cell aplasia (PRCA): preliminary results from the research on adverse drug events and reports (RADAR) group. Best Pract Res Clin Haematol 2005; 18: 481–489.

    Article  CAS  PubMed  Google Scholar 

  58. Steinbrook R . Erythropoietin, the FDA, and oncology. N Engl J Med 2007; 356: 2448–2451.

    Article  CAS  PubMed  Google Scholar 

  59. Miller CB, Lazarus HM . Erythropoietin in stem cell transplantation. Bone Marrow Transplant 2001; 27: 1011–1016.

    Article  CAS  PubMed  Google Scholar 

  60. Miller CB, Jones RJ, Zahurak ML, Piantadosi S, Burns WH, Santos GW et al. Impaired erythropoietin response to anemia after bone marrow transplantation. Blood 1992; 80: 2677–2682.

    CAS  PubMed  Google Scholar 

  61. Link H, Boogaerts MA, Fauser AA, Slavin S, Reiffers J, Gorin NC et al. A controlled trial of recombinant human erythropoietin after bone marrow transplantation. Blood 1994; 84: 3327–3335.

    CAS  PubMed  Google Scholar 

  62. Waller CF, von Lintig F, Daskalakis A, Musahl V, Lange W . Mobilization of peripheral blood progenitor cells in patients with breast cancer: a prospective randomized trial comparing rhG-CSF with the combination of rhG-CSF plus rhEpo after VIP-E chemotherapy. Bone Marrow Transplant 1999; 24: 19–24.

    Article  CAS  PubMed  Google Scholar 

  63. Hunault-Berger M, Tanguy-Schmidt A, Rachieru P, Levy V, Truchan-Graczyk M, Francois S et al. rHuEpo before high-dose therapy allows autologous peripheral stem-cell transplantation without red blood cell transfusion: a pilot study. Bone Marrow Transplant 2005; 35: 903–907.

    Article  CAS  PubMed  Google Scholar 

  64. Auerbach M, Ballard H, Trout JR, McIlwain M, Ackerman A, Bahrain H et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J Clin Oncol 2004; 22: 1301–1307.

    Article  CAS  PubMed  Google Scholar 

  65. Hedenus M, Birgegard G, Nasman P, Ahlberg L, Karlsson T, Lauri B et al. Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study. Leukemia 2007; 21: 627–632.

    Article  CAS  PubMed  Google Scholar 

  66. Henry DH, Dahl NV, Auerbach M, Tchekmedyian S, Laufman LR . Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist 2007; 12: 231–242.

    Article  CAS  PubMed  Google Scholar 

  67. Smoller BR, Kruskall MS . Phlebotomy for diagnostic laboratory tests in adults. Pattern of use and effect on transfusion requirements. N Engl J Med 1986; 314: 1233–1235.

    Article  CAS  PubMed  Google Scholar 

  68. Smoller BR, Kruskall MS, Horowitz GL . Reducing adult phlebotomy blood loss with the use of pediatric-sized blood collection tubes. Am J Clin Pathol 1989; 91: 701–703.

    Article  CAS  PubMed  Google Scholar 

  69. Spielberger R, Stiff P, Bensinger W, Gentile T, Weisdorf D, Kewalramani T et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 2004; 351: 2590–2598.

    Article  CAS  PubMed  Google Scholar 

  70. Henry DA, Carless PA, Moxey AJ, O'Connell D, Stokes BJ, McClelland B, Henderson KM et al. Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev 2001, Issue 1, Art No. CD001886.

  71. Franchini M . The use of desmopressin as a hemostatic agent: a concise review. Am J Hematol 2007; 82: 731–735.

    Article  CAS  PubMed  Google Scholar 

  72. Carless PA, Henry DA, Moxey AJ, O'Connell D, McClelland B, Henderson KM et al. Desmopressin for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev 2001, Issue 2, Art No. CD001884.

  73. Roberts HR, Monroe DM, White GC . The use of recombinant factor VIIa in the treatment of bleeding disorders. Blood 2004; 104: 3858–3864.

    Article  CAS  PubMed  Google Scholar 

  74. Dzik WH . Off-label reports of new biologics: exciting new therapy or dubious research? Examples from recombinant activated factor VII. J Intensive Care Med 2006; 21: 54–59.

    Article  PubMed  Google Scholar 

  75. Goodnough LT . Experiences with recombinant human factor VIIa in patients with thrombocytopenia. Semin Hematol 2004; 41 (1 Suppl 1): 25–29.

    Article  CAS  PubMed  Google Scholar 

  76. Pihusch M, Bacigalupo A, Szer J, von Depka Prondzinski M, Gaspar-Blaudschun B, Hyveled L et al. Recombinant activated factor VII in treatment of bleeding complications following hematopoietic stem cell transplantation. J Thromb Haemost 2005; 3: 1935–1944.

    Article  CAS  PubMed  Google Scholar 

  77. Hedner U . Dosing with recombinant factor via based on current evidence. Semin Hematol 2004; 41 (1 Suppl 1): 35–39.

    Article  CAS  PubMed  Google Scholar 

  78. Blajchman MA . Substitutes and alternatives to platelet transfusions in thrombocytopenic patients. J Thromb Haemost 2003; 1: 1637–1641.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We acknowledge Dr Amanda Davis for helpful discussion of this paper.

Author information

Authors and Affiliations

  1. Department of Medicine, Massachusetts General Hospital, Boston, MA, USA

    J M Sloan & K Ballen

Authors
  1. J M Sloan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K Ballen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to K Ballen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sloan, J., Ballen, K. SCT in Jehovah's Witnesses: the bloodless transplant. Bone Marrow Transplant 41, 837–844 (2008). https://doi.org/10.1038/bmt.2008.5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2008.5

Keywords

This article is cited by

Search

Advanced search

Quick links